KRAS and pancreatic neoplasm: The somatic genetic changes identified in these 14 patients are well in line with known driver mutations in pancreatic cancer (Kamisawa et al., 2016) (Table 3): 13 had KRAS mutations (9 × G12D), four patients had additional TP53 mutations, 10 had additional EGFR (including one with wild‐type TP53) and three had additional SMAD4 (mothers against decapentaplegic homolog 4) mutations.